What Is Tirzepatide?

Tirzepatide is a first-in-class dual-action medication that targets both GLP-1 and GIP receptors simultaneously. Originally approved for type 2 diabetes as Mounjaro, tirzepatide received FDA approval for chronic weight management under the brand name Zepbound in late 2023.

What makes tirzepatide unique is its dual mechanism. While semaglutide targets only the GLP-1 receptor, tirzepatide activates both GLP-1 and GIP pathways — producing more potent appetite suppression, greater improvements in insulin sensitivity, and significantly more weight loss in head-to-head clinical comparisons.

How Tirzepatide Works

Tirzepatide’s dual mechanism of action sets it apart from single-receptor medications:

GLP-1 Receptor Activation

Like semaglutide, tirzepatide activates GLP-1 receptors in the brain and gut, reducing appetite, slowing gastric emptying, and improving insulin secretion. This is the mechanism shared by all GLP-1 medications.

GIP Receptor Activation — The Differentiator

GIP (glucose-dependent insulinotropic polypeptide) is the second incretin hormone. By also activating GIP receptors, tirzepatide provides additional metabolic benefits:

• Enhanced fat metabolism: GIP receptors are present in adipose (fat) tissue, and their activation improves how your body processes and stores fat
• Greater insulin sensitivity: The dual-pathway approach produces more robust improvements in blood sugar control
• Potentially better tolerability: The GIP pathway may help buffer some of the GI side effects typically associated with GLP-1 medications
• Additive weight loss: Two pathways working together produce greater appetite suppression and metabolic improvement than either alone

Dosing Overview

Tirzepatide follows a structured titration schedule, beginning at a low dose and increasing every 4 weeks based on tolerance:

1. Weeks 1–4: 2.5mg/week — initial adaptation period
2. Weeks 5–8: 5mg/week — therapeutic effects begin
3. Weeks 9–12: 7.5mg/week — significant appetite reduction and weight loss
4. Weeks 13–16: 10mg/week — continued escalation based on response
5. Weeks 17–20: 12.5mg/week — approaching maximum efficacy
6. Week 21+: Up to 15mg/week — maximum dose for optimal results

Our clinical team customize this timeline based on your individual response. Some patients achieve excellent results at lower doses (7.5–10mg), while others benefit from the full 15mg. The goal is finding your optimal dose — not automatically pushing to the maximum.

Tirzepatide vs. Semaglutide

Both are effective, physician-supervised GLP-1 medications — but they’re not identical. Here’s how they compare:

Not sure which is right for you? Our clinical team evaluate your full medical profile and recommend the medication that best aligns with your health status and goals. Learn more about all GLP-1 options →

Who Is Tirzepatide For?

• BMI of 30 or greater (obesity), OR BMI of 27+ with weight-related health conditions
• Patients who have plateaued on semaglutide and need greater efficacy
• Those with concurrent insulin resistance or prediabetes (dual mechanism provides additional metabolic benefits)
• Adults seeking the most effective pharmaceutical weight loss option currently available
• Patients who prioritize maximum weight loss under physician supervision

Who Should Not Use Tirzepatide

• Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
• History of pancreatitis
• Pregnant, planning pregnancy, or breastfeeding
• Severe gastroparesis or GI motility disorders
• Allergy to tirzepatide or any formulation components

Side Effects & Safety

Tirzepatide’s side effect profile is similar to other GLP-1 medications. Most side effects are GI-related, mild to moderate, and improve during the titration period.

Compounded Tirzepatide vs. Brand-Name Zepbound

Zepbound (brand-name tirzepatide for weight loss) carries a list price exceeding $1,000/month. At MyFlowMD, our clinical team prescribe pharmaceutical-grade compounded tirzepatide from licensed, FDA-regulated pharmacies — providing the same active medication at a significantly lower cost, without the supply shortages and insurance battles that frustrate many patients.

Available Across California via Telemedicine

Whether you are in Los Angeles, San Diego, Orange County, the Inland Empire, Redding, Chico, or anywhere in between — our telemedicine platform brings physician-supervised tirzepatide therapy directly to you. Video consultations, secure messaging, and medications shipped to your door with temperature-controlled packaging.

See also: Semaglutide therapy | All GLP-1 medications